For example, it has been demonstrated that treatment with lenvatinib, programmed cell death 1 ligand 1 (PD-L1) inhibitor atezolizumab combined with bevacizumab, and programmed cell death 1 (PD-1) inhibitor sintilimab combined with bevacizumab, is effective against advanced HCC. Here, CD274 is linked to hepatocellular carcinoma.